This weekend, the FDA released its recommendation for Novavax, a vaccine designed to combat COVID-19. That in itself is not unusual; with this approval, Novavax joins the likes of vaccines from Pfizer and Moderna that have a similar purpose.

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The appro

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad population the company had originally sought. | The FDA has approved Novavax’s COVID vaccine in adults ages 65 years and older and in people between the ages of 12 and 64 who have at least one underlying health condition that puts them at high risk for severe COVID outcomes.